Effectiveness of oral and intravenous iron therapy in haemodialysis patients

International Journal of Clinical Practice

Volumn 62, Issue 3, 2008, Pages 416-422

  Jenq, C C ^b   Tian, Y C ^b   Wu, H H ^b   Hsu, P Y ^b   Huang, J Y ^b   Chen, Y C ^a,b   Fang, J T ^b   Yang, C W ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ATOFEN; C REACTIVE PROTEIN; FERRIC CHLORIDE HEXAHYDRATE; FERROUS SULFATE; IRON; SC TAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMATOCRIT; HEMODIALYSIS; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; C-REACTIVE PROTEIN; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; FERRITINS; FERROUS COMPOUNDS; HEMATINICS; HEMATOCRIT; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 38849189293     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01166.x     Document Type: Article

References (33)

1. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001 37 : S182 238.
2. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001 60 : 2406 11.
3. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995 25 : 433 9.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996 28 : 53 61.
5. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998 339 : 584 90.
6. Nagao K, Tsuchihashi K, Ura N, Nakata T, Shimamoto K. Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease. Can J Cardiol 1997 13 : 747 53.
7. Walls J. Haemoglobin - is more better? Nephrol Dial Transplant 1995 10 : 56 61.
8. Lindsay RM, Burton JA, Edward N, Dargie HJ, Prentice CRM, Kennedy AC. Dialyzer blood loss. Clin Nephrol 1973 1 : 29 34.
9. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002 22 : 479 87.
10. Lin JL, Chang MY, Tan DT, Leu ML. Short-term small-dose intravenous iron trial to detect functional iron deficiency in dialysis patients. Am J Nephrol 2001 21 : 91 7.
11. Ahsan N. Intravenous infusion of total dose iron is superior to oral iron in treatment of anaemia in peritoneal dialysis study. J Am Soc Nephrol 1998 9 : 664 8.
12. Bickford AK. Evaluation and treatment of iron deficiency in patients with kidney disease. Nutr Clin Care 2002 5 : 225 30.
13. Heath AL, Fairweather-Tait SJ. Clinical implications of changes in the modern diet: iron intake, absorption and status. Best Pract Res Clin Haematol 2002 15 : 225 41.
14. Boddy K, Lawson DH, Linton AL, Will G. Iron metabolism in patients with chronic renal failure. Clin Sci 1970 39 : 115 21.
15. Silverberg DS, Blum M, Agbaria Z et al. Intravenous iron for treatment of predialysis anemia. Kidney Int 1999 69 : S79 85.
16. Maksimowicz-Mckinnon K, Bhatt DL, Calabrese LH. Recent advances in vascular inflammation: C-reactive protein and other inflammatory biomarkers. Curr Opin Rheumatol 2004 16 : 18 24.
17. Horl WH. Adjunctive therapy in anaemia management. Nephrol Dial Transplant 2002 17 (Suppl. 5 56 9.
18. Balagopalakrishna C, Paka L, Pillarisetti S, Goldberg IJ. Lipolysis-induced iron release from diferric transferrin: possible role of lipoprotein lipase in LDL oxidation. J Lipid Res 1999 40 : 1347 56.
19. Khovidhunkit W, Kim MS, Memon RA et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004 45 : 1169 96.
20. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant 2004 19 : 2570 5.
21. Ahmad I, Zhan M, Miller M. High prevalence of C-reactive protein elevation with normal triglycerides (100-149 mg/dl): are triglyceride levels below 100 mg/dl more optimal in coronary heart disease risk assessment? Am J Med Sci 2005 329 : 173 7.
22. Stangl GI, Kirchgessner M. Different degrees of moderate iron deficiency modulate lipid metabolism of rats. Lipids 1998 33 : 889 95.
23. Lewis M, Iammarino RM. Lipemia in rodent iron deficiency. J Lab Clin Med 1971 78 : 547 54.
24. Amine EK, Hegsted DM. Iron deficiency lipemia in the rat and chick. J Nutr 1971 101 : 1575 82.
25. Sherman AR, Guthrie HA, Wolinsky I, Zulak IM. Iron deficiency hyperlipidemia in 18-day-old rat pups: effects of milk lipids, lipoprotein lipase, and triglyceride synthesis. J Nutr 1978 108 : 152 62.
26. Cunnane SC, McAdoo KR. Iron intake influences essential fatty acid and lipid composition of rat plasma and erythrocytes. J Nutr 1987 117 : 1514 9.
27. Kirk EA, Heinecke JW, LeBoeuf RC. Iron overload diminishes atherosclerosis in apoE-deficient mice. J Clin Invest 2001 107 : 1545 53.
28. Choi JW, Kim SK, Pai SH. Changes in serum lipid concentrations during iron depletion and after iron supplementation. Ann Clin Lab Sci 2001 31 : 151 6.
29. Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977 87 : 710 3.
30. Chen CH, Cheng CH, Wu MJ, Chen KJ, Lee WC, Shu KH. Tinzaparin (Innohep®), a low-molecular-weight heparin, reduces complications of standard heparin in hemodialysis patients. Acta Nephrol 2004 18 : 151 6.
31. Chuang CL, Liu RS, Wei YH, Huang TP, Tarng DC. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003 18 : 370 7.
32. Hsu PY, Lin CL, Yu CC et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004 17 : 693 700.
33. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001 16 : 1863 9.